Clinical Characteristics and Outcomes of Hospitalized COVID-19 Patients in a MERS-CoV Referral Hospital during the Peak of the Pandemic
Barry et al.
, Clinical Characteristics and Outcomes of Hospitalized COVID-19 Patients in a MERS-CoV Referral Hospital during..
, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.03.058
605 hospitalized patients in Saudi Arabia showing no mortality with HCQ (only 6 patients received HCQ).
risk of death, 98.9% lower, RR 0.01, p = 0.60, treatment 0 of 6 (0.0%), control 91 of 599 (15.2%), NNT 6.6, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Barry et al., 23 Mar 2021, retrospective, Saudi Arabia, peer-reviewed, 14 authors.
Abstract: International Journal of Infectious Diseases 106 (2021) 43–51
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier.com/locate/ijid
Clinical characteristics and outcomes of hospitalized COVID-19
patients in a MERS-CoV referral hospital during the peak of the
Mazin Barrya,* , Nouf Althabita , Layan Akkielaha , AbdulEllah AlMohayaa,b ,
Muath Alotaibia , Sara Alhasania , Abdulwahab Aldreesa , Abdulaziz AlRajhia , Ali AlHijia ,
Fahad Almajida , Aynaa AlSharidia , Fatimah S. Al-Shahrania , Naif H. Alotaibia ,
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
Internal Medicine Department, Ad-Dariya Hospital, Ministry of Health, Riyadh, Saudi Arabia
Microbiology Unit, Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
A R T I C L E I N F O
A B S T R A C T
Received 8 January 2021
Received in revised form 16 March 2021
Accepted 18 March 2021
Objective: To describe the clinical characteristics and outcomes of hospitalized coronavirus disease 2019
(COVID-19) patients in a middle east respiratory syndrome coronavirus (MERS-CoV) referral hospital
during the peak months of the pandemic.
Design: A single-center case series of hospitalized individuals with conﬁrmed severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infections in King Saud University Medical City (KSUMC), an
academic tertiary care hospital in Riyadh, Saudi Arabia.
Clinical and biochemical markers were documented. Risks for ventilatory support, intensive care unit
(ICU) admission and death are presented.
Results: Out of 12,688 individuals tested for SARS-CoV-2 by real time reverse transcriptase polymerase
reaction (RT-PCR) from June 1 to August 31, 2020, 2,683 (21%) were positive for COVID-19. Of the latter,
605 (22%) patients required hospitalization with a median age of 55, 368 (61%) were male. The most
common comorbidities were hypertension (43%) and diabetes (42%). Most patients presented with fever
(66%), dyspnea (65%), cough (61%), elevated IL-6 (93.5%), D-dimer (90.1%), CRP (86.1%), and lymphopenia
(41.7%). No MERS-CoV co-infection was detected. Overall, 91 patients (15%) died; risk factors associated
with mortality were an age of 65 years or older OR 2.29 [95%CI 1.43–3.67], presence of two or more
comorbidities OR 3.17 [95%CI 2.00–5.02], symptoms duration of seven days or less OR 3.189 [95%CI (1.64 –
6.19]) lymphopenia OR 3.388 [95%CI 2.10–5.44], high CRP OR 2.85 [95%CI 1.1–7.32], high AST OR 2.95 [95%
CI 1.77–4.90], high creatinine OR 3.71 [95%CI 2.30–5.99], and high troponin-I OR 2.84 [95%CI 1.33–6.05].
Conclusion: There is a signiﬁcant increase in severe cases of COVID-19. Mortality was associated with
older age, shorter symptom duration, high CRP, low lymphocyte count, and end-organ damage.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.